Barcelona
 
Home
Welcome Note
Faculty List
Committees
Timetable
Scientific Program
Satellite Symposia
Thursday
Friday
Saturday
Sunday
Abstracts
Abstract Submission
Best Abstract Awards
Sponsorship & Exhibition
Sponsors
Exhibitors
CME
Registration
Invitation Letter
Accommodation
Poster Presentation
Poster List
Abstracts List
Poster Presentation Guidelines
General Information
Before you Travel
Things to Do
Italian Agent
Previous and upcoming CODHy Congresses
Partners
Links
Contact Us

  Scientific Program Print
Friday

Hall A
 
Plenary Session
08:30-10:00
Diabetes and Cancer
Chairs: S. Del Prato, Italy and I. Raz, Israel 
08:30-08:35 Introduction
08:35-08:55
Pathogenesis of cancers in diabetes and obesity
D. Leroith, USA
08:55-09:15
Insulin therapy and cancer
P. Home, UK
09:15-09:35
Oral agents and cancer (metformin, sulfonylureas, thiazolidinediones)
R.A. DeFronzo, USA
09:35-09:55
Newer therapies and cancer (incretin and SGLT2)
M. Nauck, Germany
09:55-10:00 Discussion: Do we need malignancy outcome studies?

10:0:00-10:30
Coffee Break

Session 2
10:30-12:00
Controversies in Diabetes Treatment
Chairs: P. Djordjevic, Serbia & B. Gallwitz, Germany
10:30-10:35 Introduction

 
 
 
 
 
 

 
10:35-10:50
10:50-11:05
11:05-11:20
How to start pharmacologic treatment?
Patho-physiological driven approach vs. Guideline approach
Patho-physiological driven approach: R.A. DeFronzo, USA
Guideline approach: I. Raz, Israel
Discussion

 
 
 
 

 
11:20-11:35
11:35-11:50
11:50-12:00
How do we continue treatment of secondary failure?
Incretin vs. insulin treatment
Incretin: B. Gallwitz, USA
Insulin: R.G. Bretzel, Germany
Discussion

12:00-13:00
Lunch Break

Session 3
13:00-15:00
Diabetes, Obesity and Hypertension
Chairs: A. Lejnieks, Latvia & E. Grossman, Israel
13:00-13:05 Introduction
 
 
 
 
13:05-13:20
13:20-13:35
Should we be targeting subclinical organ damage?
Yes: E. Grossman, Israel
No: G. Mancia, Italy
 
 
 
 
 
 
 
 
 
 
 
 
13:35-13:50
 
13:50-14:05
 
14:05-14:20
 
14:20-14:35
 

14:35-15:00
Should our targets for control be different in the elderly?
Obesity
C. Tsigos, Greece
Blood pressure control
G. Grassi, Italy
Lipid control
R. Bitzur, Israel
Blood glucose control
Y. Kleinman, Israel
 
Discussion
 
15:00-15:30
Coffee Break
 
Session 4
15:30-17:00
Diabetes and Related Disorders
Chair: P. Home, UK & S. Sadikot, India
15:30-15:35
Introduction

15:35-15:55
 
Sleep disorders
S. Sadikot, India

15:55-16:15
Pancreatitis
G. Marchesini, Italy

16:15-16:35

 
16:35-17:00
Diabetes, Dysglycemia and cognitive disfunction
T. Cukierman-Yaffee. Israel
 
Discussion

Hall B
 
Session 5
10:30-12:00
News in Hypertension
Chairs: Y. Yodfat, Israel & G. Mancia, Italy
10:30-10:35
Introduction
 
10:35-10:55
Individualization of the management of hypertension
G. Mancia, Italy


 
10:55-11:05
11:05-11:15
11:15-11:25
Blood pressure (BP) variability or average BP is the main determinant of future cardiovascular (CV) outcomes
Pro BP-variability: G. Parati, Italy
Pro-average BP: P. Nilsson, Sweden
Discussion
 
 
11:25-11:35
11:35-11:45
11:45-12:00
Diagnosis of hypertension should be by ambulatory monitoring
Pro: E. Grossman, Israel
Con: P. Nilsson, Sweden
Discussion

12:00-13:00
Lunch Break

Session 6
13:00-15:00
Obesity and Weight Loss
Chairs: D. Micic, Serbia & V. Hainer, Czech Republic
13:00-13:05
Introduction
 
 
13:05-13:20
13:20-13:35
Is obesity a brain disease?
Yes: N. Stern, Israel
No: N. Finer, UK

 
13:35-13:50
13:50-14:05
Cardiovascular risk factor: The obesity paradox - Does it exist?
Against: E. Standl, Germany
In favor: V. Hainer, Czech Republic
 
14:05-14:20
14:20-14:35
14:35-15:00
Physical exercise is a core element for every patient
Yes: P.P. De Feo, Italy
No: P. Schwarz, Germany
Discussion
 
15:00-15:30
Coffee Break
 
Session 7
15:30-17:00
Bariatric Surgery
Chairs: J.C. Holm, Denmark & R. Taylor, UK
15:30-15:35
Introduction


15:35-15:50
15:50-16:05
16:05-16:15
Mechanism of metabolic advantage after bariatic surgery
It's all food restrictions: R. Taylor, UK
It's all gastro-intestinal factors: F.K. Knop, Denmark
Discussion

 
16:15-16:30
16:30-16:45
16:45-17:00
Can surgery during adolescence be justified?
Yes: R. Weiss, Israel
No: J.C. Holm, Denmark
Discussion
Hall C
 
Session 8
10:30-12:00
Unmet Needs in Obesity
Chairs: L. Van Gaal, Belgium & R. Weiss, Israel
10:30-10:35
Introduction

10:35-10:55
Obesity treatments: The state of the art
L. Van Gaal, Belgium

10:55-11:15
Bariatric surgery in the prevention of type 2 diabetes: Long term experiences from the SOS study
L. Carlsson, Sweden

11:15-11:35
 
 
11:35-12:00
From bariatric surgery to bariatric pill
G. Lieberman, Israel
 
Discussion

12:00-13:00
Lunch Break

Session 9
13:00-15:00
The Kidney As a New Therapeutic Partner
Chair: G. Schernthaner, Austria & M. Puig Domingo, Spain 
Supported by Janssen, Pharmaceutical Companies of Johnson & Johnson
13:00-13:05
Introduction
 
13:05-13:25
Hyperglycaemia, hypertension, obesity, and the kidney in people with T2D
L. Van Gaal, Belgium
 
13:25-13:45
The kidney as a new therapeutic partner
J. Wilding, UK

13:45-14:05
Clinical potential of SGLT-2 inhibition
J. Seufert, Germany
14:05-14:25
How this new approach may help tackle clinical inertia
M. Puig Domingo, Spain
14:25-15:00 Discussion
 
15:00-15:30
Coffee Break
 
Session 10
15:30-17:00
Ongoing Discussions in Diabetes and Metabolic Syndrome
Chairs: J. Skrha, Czech Republic & A. Ceriello, Spain
15:30-15:35
Introduction
 

15:35-15:55
15:55-16:15
Postprandial hyperglycaemic variability: Should we care?
Yes: A. Ceriello, Spain
No: E.S. Kilpatrick, UK
 
16:15-16:35
 
 
16:35-17:00
NAFLD/NASH- Is it an independent predictor of CV disease?
E. Bonora, Italy
 
Discussion

 
 17:00-19:00
Bristol-Myers Squibb / AstraZeneca Satellite Symposium

Home    Sponsors    Regesteration    Contact Us   
 
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 16/01/2014 Created by     WebStudio.co.il